Ratings Teladoc Health, Inc.

Equities

TDOC

US87918A1051

Real-time Estimate Cboe BZX Other stock markets 10:11:21 2024-04-23 am EDT			5-day change	1st Jan Change
13.88 ^USD	+4.40%		+6.40%	-35.17%

Apr. 12	Teladoc Health, Inc. Announces Resignation of Richard J. Napolitano as Chief Accounting Officer, Effective May 3, 2024	CI
Apr. 08	Deutsche Bank Cuts Teladoc's Price Target to $18 From $22, Maintains Hold Rating	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

With regards to fundamentals, the enterprise value to sales ratio is at 0.95 for the current period. Therefore, the company is undervalued.
The company appears to be poorly valued given its net asset value.
The company has a low valuation given the cash flows generated by its activity.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
TELADOC HEALTH, INC.	-38.28%	2.25B		D+
HIMS & HERS HEALTH, INC.	+33.48%	2.55B		-
TALKSPACE, INC.	+20.87%	519M		-
QDM INTERNATIONAL INC.	+42.77%	467M	-	-
AMERICAN WELL CORPORATION	-62.93%	164M		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes